 Yong-Chen Lu
Concepts (182)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antigens, Neoplasm | 14 | 2025 | 147 | 4.280 |
Why?
| | Receptors, Antigen, T-Cell | 11 | 2025 | 51 | 3.190 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 18 | 2025 | 78 | 3.120 |
Why?
| | Immunotherapy | 7 | 2025 | 244 | 2.610 |
Why?
| | T-Lymphocytes | 10 | 2025 | 329 | 2.600 |
Why?
| | Immunotherapy, Adoptive | 8 | 2019 | 167 | 2.380 |
Why?
| | Neoplasms | 10 | 2024 | 1308 | 2.310 |
Why?
| | CD4-Positive T-Lymphocytes | 5 | 2024 | 165 | 1.570 |
Why?
| | Cancer Vaccines | 4 | 2021 | 78 | 1.360 |
Why?
| | High-Throughput Nucleotide Sequencing | 3 | 2021 | 179 | 1.200 |
Why?
| | Mutation | 12 | 2019 | 1344 | 0.910 |
Why?
| | Single-Cell Analysis | 3 | 2022 | 73 | 0.740 |
Why?
| | CD8-Positive T-Lymphocytes | 9 | 2025 | 132 | 0.730 |
Why?
| | Immune System | 1 | 2020 | 41 | 0.660 |
Why?
| | Alcohol Oxidoreductases | 1 | 2019 | 13 | 0.630 |
Why?
| | HLA-DP beta-Chains | 2 | 2017 | 2 | 0.590 |
Why?
| | Neoplasm Proteins | 2 | 2017 | 328 | 0.570 |
Why?
| | Urinary Bladder Neoplasms | 1 | 2019 | 165 | 0.550 |
Why?
| | Genetic Therapy | 2 | 2017 | 122 | 0.540 |
Why?
| | DNA-Binding Proteins | 1 | 2019 | 426 | 0.510 |
Why?
| | Melanoma | 3 | 2016 | 279 | 0.510 |
Why?
| | Immunodominant Epitopes | 2 | 2015 | 9 | 0.450 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 4 | 2019 | 69 | 0.450 |
Why?
| | Humans | 31 | 2025 | 52593 | 0.420 |
Why?
| | Protein Phosphatase 1 | 1 | 2013 | 7 | 0.420 |
Why?
| | Cytokines | 4 | 2019 | 626 | 0.410 |
Why?
| | Phosphoprotein Phosphatases | 1 | 2013 | 17 | 0.410 |
Why?
| | Animals | 12 | 2024 | 13507 | 0.410 |
Why?
| | Lymphocyte Activation | 5 | 2021 | 163 | 0.410 |
Why?
| | Proto-Oncogene Proteins c-rel | 2 | 2010 | 5 | 0.400 |
Why?
| | Antibodies, Monoclonal | 1 | 2016 | 478 | 0.380 |
Why?
| | Neoplasm Metastasis | 3 | 2022 | 239 | 0.340 |
Why?
| | Colorectal Neoplasms | 3 | 2019 | 295 | 0.340 |
Why?
| | CCAAT-Enhancer-Binding Protein-beta | 1 | 2009 | 5 | 0.320 |
Why?
| | Toll-Like Receptors | 1 | 2009 | 27 | 0.310 |
Why?
| | CCAAT-Enhancer-Binding Protein-delta | 1 | 2009 | 23 | 0.310 |
Why?
| | Lipopolysaccharides | 2 | 2022 | 206 | 0.300 |
Why?
| | Transcriptome | 2 | 2022 | 368 | 0.300 |
Why?
| | Glioblastoma | 2 | 2021 | 97 | 0.300 |
Why?
| | Toll-Like Receptor 4 | 1 | 2008 | 50 | 0.280 |
Why?
| | Signal Transduction | 5 | 2019 | 1714 | 0.280 |
Why?
| | Adoptive Transfer | 3 | 2018 | 29 | 0.250 |
Why?
| | Cells, Cultured | 5 | 2021 | 1588 | 0.250 |
Why?
| | Gene Expression Profiling | 2 | 2021 | 1110 | 0.230 |
Why?
| | Autoantigens | 2 | 2015 | 52 | 0.230 |
Why?
| | T-Lymphocytes, Regulatory | 2 | 2016 | 84 | 0.220 |
Why?
| | Gene Library | 2 | 2014 | 42 | 0.210 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2025 | 200 | 0.200 |
Why?
| | Nephritis | 1 | 2022 | 23 | 0.190 |
Why?
| | Receptors, Immunologic | 1 | 2022 | 36 | 0.190 |
Why?
| | Clone Cells | 2 | 2019 | 76 | 0.190 |
Why?
| | Middle Aged | 9 | 2025 | 13096 | 0.190 |
Why?
| | Ureteral Obstruction | 1 | 2022 | 62 | 0.180 |
Why?
| | Liver Neoplasms | 1 | 2025 | 332 | 0.180 |
Why?
| | HLA-A Antigens | 2 | 2019 | 11 | 0.180 |
Why?
| | Human papillomavirus 16 | 1 | 2021 | 44 | 0.180 |
Why?
| | Adaptor Proteins, Signal Transducing | 2 | 2014 | 201 | 0.180 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2022 | 224 | 0.180 |
Why?
| | T-Cell Antigen Receptor Specificity | 2 | 2017 | 4 | 0.170 |
Why?
| | Membrane Glycoproteins | 1 | 2022 | 242 | 0.170 |
Why?
| | Papillomavirus Vaccines | 1 | 2021 | 69 | 0.170 |
Why?
| | Interleukin-2 | 2 | 2017 | 69 | 0.160 |
Why?
| | Mucin-4 | 1 | 2019 | 1 | 0.160 |
Why?
| | Smad5 Protein | 1 | 2019 | 2 | 0.160 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2022 | 203 | 0.150 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2021 | 299 | 0.150 |
Why?
| | Cell Differentiation | 1 | 2021 | 673 | 0.150 |
Why?
| | Flow Cytometry | 3 | 2016 | 400 | 0.140 |
Why?
| | Epitopes, T-Lymphocyte | 2 | 2014 | 26 | 0.140 |
Why?
| | Administration, Intravenous | 1 | 2017 | 74 | 0.140 |
Why?
| | Colonic Neoplasms | 1 | 2019 | 163 | 0.130 |
Why?
| | Membrane Proteins | 1 | 2019 | 337 | 0.130 |
Why?
| | Male | 7 | 2025 | 26863 | 0.130 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2022 | 606 | 0.130 |
Why?
| | Aged | 3 | 2025 | 10191 | 0.130 |
Why?
| | Exome | 2 | 2014 | 55 | 0.130 |
Why?
| | CTLA-4 Antigen | 1 | 2016 | 23 | 0.130 |
Why?
| | Cell Line, Tumor | 2 | 2017 | 1436 | 0.130 |
Why?
| | Gene Expression Regulation | 2 | 2019 | 1006 | 0.130 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 2016 | 42 | 0.130 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2016 | 41 | 0.120 |
Why?
| | Transcription Factors | 1 | 2019 | 566 | 0.120 |
Why?
| | Protein Binding | 2 | 2014 | 673 | 0.120 |
Why?
| | Transplantation, Autologous | 1 | 2017 | 488 | 0.120 |
Why?
| | Female | 11 | 2025 | 28262 | 0.120 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2015 | 42 | 0.120 |
Why?
| | Adult | 7 | 2021 | 14170 | 0.120 |
Why?
| | Neutrophils | 2 | 2014 | 148 | 0.120 |
Why?
| | Treatment Outcome | 4 | 2021 | 5486 | 0.120 |
Why?
| | Time Factors | 2 | 2021 | 3000 | 0.120 |
Why?
| | Respiratory Burst | 1 | 2014 | 4 | 0.110 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2019 | 857 | 0.110 |
Why?
| | Hepatitis B e Antigens | 1 | 2014 | 4 | 0.110 |
Why?
| | Histocompatibility Antigens | 1 | 2014 | 5 | 0.110 |
Why?
| | Chemotaxis, Leukocyte | 1 | 2014 | 13 | 0.110 |
Why?
| | Epitope Mapping | 1 | 2014 | 6 | 0.110 |
Why?
| | Bile Ducts, Intrahepatic | 1 | 2014 | 13 | 0.110 |
Why?
| | Bile Duct Neoplasms | 1 | 2014 | 28 | 0.110 |
Why?
| | Cholangiocarcinoma | 1 | 2014 | 26 | 0.110 |
Why?
| | Th1 Cells | 1 | 2014 | 55 | 0.110 |
Why?
| | Monocytes | 1 | 2014 | 129 | 0.110 |
Why?
| | Alleles | 1 | 2014 | 278 | 0.100 |
Why?
| | Amino Acid Sequence | 1 | 2014 | 574 | 0.100 |
Why?
| | Peptides | 1 | 2014 | 236 | 0.100 |
Why?
| | Gene Knockdown Techniques | 1 | 2013 | 110 | 0.100 |
Why?
| | NF-kappa B | 2 | 2011 | 329 | 0.100 |
Why?
| | Genes, T-Cell Receptor | 2 | 2022 | 5 | 0.100 |
Why?
| | Base Sequence | 1 | 2013 | 637 | 0.090 |
Why?
| | TNF Receptor-Associated Factor 2 | 1 | 2011 | 3 | 0.090 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 582 | 0.090 |
Why?
| | Molecular Sequence Data | 1 | 2013 | 773 | 0.090 |
Why?
| | Autoimmunity | 1 | 2011 | 34 | 0.090 |
Why?
| | Cell Line | 1 | 2014 | 1033 | 0.090 |
Why?
| | Forkhead Transcription Factors | 1 | 2012 | 121 | 0.090 |
Why?
| | Disease Progression | 1 | 2014 | 873 | 0.090 |
Why?
| | Clinical Trials as Topic | 1 | 2013 | 472 | 0.090 |
Why?
| | Lung Neoplasms | 1 | 2016 | 634 | 0.080 |
Why?
| | Clonal Anergy | 1 | 2010 | 13 | 0.080 |
Why?
| | Mice | 4 | 2022 | 5958 | 0.080 |
Why?
| | Protein Kinase C | 1 | 2010 | 70 | 0.080 |
Why?
| | Dendritic Cells | 2 | 2022 | 136 | 0.080 |
Why?
| | Remission Induction | 2 | 2021 | 219 | 0.080 |
Why?
| | Isoenzymes | 1 | 2010 | 167 | 0.080 |
Why?
| | Interleukin-1 Receptor-Associated Kinases | 1 | 2009 | 11 | 0.080 |
Why?
| | Myeloid Differentiation Factor 88 | 1 | 2009 | 34 | 0.080 |
Why?
| | Breast Neoplasms | 1 | 2018 | 1205 | 0.080 |
Why?
| | Antineoplastic Agents | 1 | 2017 | 1221 | 0.080 |
Why?
| | Transcriptional Activation | 1 | 2009 | 128 | 0.080 |
Why?
| | Inflammation Mediators | 1 | 2009 | 116 | 0.070 |
Why?
| | Antigen Presentation | 2 | 2019 | 26 | 0.070 |
Why?
| | Cell Separation | 2 | 2019 | 74 | 0.070 |
Why?
| | Complement C3a | 1 | 2007 | 3 | 0.070 |
Why?
| | Complement C5a | 1 | 2007 | 3 | 0.070 |
Why?
| | Macrophages | 1 | 2009 | 379 | 0.060 |
Why?
| | Lymphocyte Count | 2 | 2016 | 20 | 0.060 |
Why?
| | Tumor Microenvironment | 1 | 2025 | 255 | 0.050 |
Why?
| | Th17 Cells | 1 | 2022 | 27 | 0.050 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2021 | 24 | 0.050 |
Why?
| | Neoplasm Grading | 1 | 2021 | 126 | 0.050 |
Why?
| | Gene Regulatory Networks | 1 | 2022 | 111 | 0.040 |
Why?
| | Arginine | 1 | 2022 | 182 | 0.040 |
Why?
| | Nitric Oxide | 1 | 2022 | 244 | 0.040 |
Why?
| | Host-Pathogen Interactions | 1 | 2021 | 144 | 0.040 |
Why?
| | Blotting, Western | 2 | 2011 | 593 | 0.040 |
Why?
| | Transduction, Genetic | 1 | 2019 | 44 | 0.040 |
Why?
| | Immunologic Memory | 1 | 2019 | 32 | 0.040 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2019 | 34 | 0.040 |
Why?
| | Lung | 2 | 2016 | 501 | 0.040 |
Why?
| | Coculture Techniques | 1 | 2019 | 145 | 0.040 |
Why?
| | Transplantation Conditioning | 1 | 2019 | 93 | 0.040 |
Why?
| | Lymphatic Metastasis | 1 | 2019 | 211 | 0.040 |
Why?
| | Phenotype | 2 | 2012 | 800 | 0.040 |
Why?
| | Molecular Targeted Therapy | 1 | 2019 | 134 | 0.040 |
Why?
| | Cell Proliferation | 1 | 2021 | 1029 | 0.030 |
Why?
| | HLA-DRB1 Chains | 1 | 2017 | 5 | 0.030 |
Why?
| | Antigen-Presenting Cells | 1 | 2017 | 22 | 0.030 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2018 | 140 | 0.030 |
Why?
| | Pilot Projects | 1 | 2019 | 721 | 0.030 |
Why?
| | Cross Reactions | 1 | 2016 | 41 | 0.030 |
Why?
| | HLA-C Antigens | 1 | 2015 | 5 | 0.030 |
Why?
| | ras Proteins | 1 | 2015 | 64 | 0.030 |
Why?
| | Inflammation | 2 | 2011 | 644 | 0.030 |
Why?
| | Proto-Oncogene Proteins | 1 | 2015 | 151 | 0.030 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2014 | 47 | 0.030 |
Why?
| | Chemokines | 1 | 2014 | 79 | 0.030 |
Why?
| | Receptor, erbB-2 | 1 | 2014 | 80 | 0.030 |
Why?
| | Vaccination | 1 | 2016 | 299 | 0.030 |
Why?
| | B-Lymphocytes | 1 | 2014 | 180 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 2014 | 496 | 0.030 |
Why?
| | Dose-Response Relationship, Immunologic | 1 | 2012 | 13 | 0.020 |
Why?
| | Whole-Body Irradiation | 1 | 2012 | 128 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2011 | 460 | 0.020 |
Why?
| | Apoptosis | 1 | 2014 | 1121 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2011 | 910 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2010 | 564 | 0.020 |
Why?
| | Receptor, Anaphylatoxin C5a | 1 | 2007 | 3 | 0.020 |
Why?
| | Receptors, Chemokine | 1 | 2007 | 13 | 0.020 |
Why?
| | Complement Activation | 1 | 2007 | 23 | 0.020 |
Why?
| | Cattle | 1 | 2007 | 207 | 0.020 |
Why?
| | Actins | 1 | 2007 | 117 | 0.020 |
Why?
| | Hematopoietic Stem Cells | 1 | 2007 | 188 | 0.010 |
Why?
| | Fibroblasts | 1 | 2007 | 359 | 0.010 |
Why?
|
|
Lu's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|